LSDMDMAKetaminePsilocybin

A Nationwide Study Comparing Mental Health Professionals' Willingness to Try Hallucinogenic Drugs in Basic Research or Clinical Practice

This survey study (n=347) examined Israeli mental health professionals' attitudes toward recreational drug users and willingness to use five hallucinogens (LSD, MDMA, ketamine, cannabis, psilocybin) in research or clinical practice. Compared to nurses and paramedics, psychiatrists were more familiar with the potential therapeutic role of psychedelics and had a higher willingness to conduct research or use such substances for clinical purposes. However, psychiatrists were also the most susceptible to personal bias, as evidenced by cases wherein negative attitudes toward recreational users impeded their support for psychedelic within the context of clinical treatments or research.

Authors

  • Ginati, Y. D.
  • Ben-Sheetrit, J.
  • Lev-Ran, S.

Published

Journal of Psychoactive Drugs
individual Study

Abstract

Introduction

This study explored whether personal attitudes toward drug users are associated with professional approaches and whether the association between personal and professional attitudes varies across different mental health professions.

Methods

Participants (N = 347) included medical (psychiatrists and psychiatric nurses) and other (clinical psychologists and social workers) mental health professions from all 13 mental health centers in Israel. They completed questionnaires aimed to assess familiarity with medical usage of hallucinogenic drugs, personal attitudes toward recreational drug users and willingness to use five hallucinogens in research of clinical practice. Hypotheses were tested using multiple-group structural equation modeling (SEM).

Results

Psychiatrists reported the highest levels of familiarity with and willingness to use all types of hallucinogenic drugs, as compared to other mental health professionals. Psychiatrists held the strongest belief in the potential utility of hallucinogenic drugs; yet, their personal attitudes toward drug users affected negatively their willingness to try hallucinogenic drugs in clinical practice. This was the only significant association that was found.

Discussion

Future research and treatment programs should address the topic of hallucinogenic drug therapy, and specifically the need to separate between individual beliefs and professional clinical decision-making.

Available with Blossom Pro

Research Summary of 'A Nationwide Study Comparing Mental Health Professionals' Willingness to Try Hallucinogenic Drugs in Basic Research or Clinical Practice'

Expert Research Summaries

Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.

Full Text PDF

Full Paper PDF

Create a free account to open full-text PDFs.

Study Details

  • Study Type
    individual
  • Journal
  • Compounds
  • APA Citation

    Ginati, Y. D., Madjar, N., Ben-Sheetrit, J., Lev-Ran, S., Weizman, A., & Shoval, G. (2022). A Nationwide Study Comparing Mental Health Professionals' Willingness to Try Hallucinogenic Drugs in Basic Research or Clinical Practice. Journal of Psychoactive Drugs, 54(2), 177-187. https://doi.org/10.1080/02791072.2021.1941444

References (14)

Papers cited by this study that are also in Blossom

A Survey of American Psychiatrists’ Attitudes Toward Classic Hallucinogens

Barnett, B. S., Siu, W. O., Pope Jr, H. G. · Journal of Nervous and Mental Disease (2018)

Lysergic acid diethylamide: a drug of ‘use’?

Das, S., Barnwal, P., Ramasamy, A. et al. · Therapeutic Advances in Psychopharmacology (2016)

Persisting Reductions in Cannabis, Opioid, and Stimulant Misuse After Naturalistic Psychedelic Use: An Online Survey

Garcia-Romeu, A., Davis, A. K., Griffiths, R. R. et al. · Frontiers in Psychiatry (2020)

121 cited
Clinical Applications of Hallucinogens: A Review

Garcia-Romeu, A., Kersgaard, B., Addy, P. H. · Experimental and Clinical Psychopharmacology (2016)

174 cited
Current perspectives on psychedelic therapy: use of serotonergic hallucinogens in clinical interventions

Richards, W. A., Garcia-Romeu, A. · International Review of Psychiatry (2018)

Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction

Johnson, M. W., Garcia-Romeu, A., Cosimano, M. P. et al. · Journal of Psychopharmacology (2014)

Human hallucinogen research: guidelines for safety

Johnson, M. W., Richards, W. A., Griffiths, R. R. · Journal of Psychopharmacology (2008)

Show all 14 references
Psychedelics in the treatment of unipolar mood disorders: a systematic review

Rucker, J., Young, A. H., Jelen, L. A. et al. · Journal of Psychopharmacology (2016)

Psilocybin-Assisted Therapy: A Review of a Novel Treatment for Psychiatric Disorders

Thomas, K., Malcolm, B., Lastra, D. · Journal of Psychoactive Drugs (2017)

Potential Psychiatric Uses for MDMA

Yazar-Klosinski, B., Mithoefer, M. C. · Clinical Pharmacology and Therapeutics (2016)

Cited By (1)

Papers in Blossom that reference this study

Your Personal Research Library

Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.

A Nationwide Study Comparing Mental Health... — Research Summary & Context | Blossom